Financing structural interventions: Going beyond HIV-only value for money assessments

AIDS

Volumn 28, Issue 3, 2014, Pages 425-434

  Remme, Michelle ^a   Vassall, Anna ^a   Lutz, Brian ^b   Luna, Jorge ^c   Watts, Charlotte ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNITED NATIONS DEVELOPMENT PROGRAMME   (United States)

^c Howard Hughes Medical Institute   (United States)

Author keywords

Cofinancing; Cost effectiveness; Cross sectoral; HIV AIDS; Structural interventions; Value for money

Indexed keywords

ADOLESCENT; BEHAVIOR THERAPY; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; MALAWI; PREGNANCY; RESOURCE ALLOCATION; YOUNG ADULT;

EID: 84894034846     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000076     Document Type: Article

References (71)

1. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2197-2223.
2. Seeley J, Watts CH, Kippax S, Russell S, Heise L, Whiteside A. Addressing the structural drivers of HIV: a luxury or necessity for programmes? J Int AIDS Soc 2012; 15 (Suppl 1):1-4.
3. WHO. Rio Political Declaration on Social Determinants of Health. World Conference on Social Determinants of Health, Rio de Janeiro, Brazil.World Health Organisation; 2011.
4. Gupta GR, Parkhurst JO, Ogden Ja, Aggleton P, Mahal A. Structural approaches to HIV prevention. Lancet 2008; 372: 764-775.
5. Blankenship KM, Friedman SR, Dworkin S, Mantell JE. Structural interventions: concepts, challenges and opportunities for research. J Urban Health 2006; 83:59-72.
6. Piot P, Bartos M, Larson H, Zewdie D, Mane P. Coming to terms with complexity: a call to action for HIV prevention. Lancet 2008; 372:845-859.
7. Baird SJ, Garfein RS, McIntosh CT, Ozler B. Effect of a cash transfer programme for schooling on prevalence of HIV and herpes simplex type 2 in Malawi: a cluster randomised trial. Lancet 2012; 379:1320-1329.
8. Pronyk PM, Hargreaves JR, Kim JC, Morison La, Phetla G, Watts C, et al. Effect of a structural intervention for the prevention of intimate-partner violence and HIV in rural South Africa: a cluster randomised trial. Lancet 2006; 368:1973-1983.
9. UNAIDS. Meeting the investment challenge: tipping the dependency balance. Geneva: UNAIDS; 2012.
10. Hecht R, Stover J, Bollinger L, Muhib F, Case K, de Ferranti D. Financing of HIV/AIDS programme scale-up in low-income and middle-income countries, 2009-31. Lancet 2010; 376: 1254-1260.
11. Lule E, Haacker M. The fiscal dimension of HIV/AIDS in Botswana, South Africa, Swaziland, and Uganda. Washington, DC: The World Bank; 2012.
12. Haacker M. Financing HIV/AIDS programs in sub-Saharan Africa. Health Aff (Millwood) 2009; 28:1606-1616.
13. Schwartländer B, Stover J, Hallett T, Atun R, Avila C, Gouws E, et al. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet 2011; 377:2031-2041.
14. UNAIDS. Together we will end AIDS. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2012.
15. Garg CC, Evans DB, Dmytraczenko T, Izazola-Licea JA, Tangcharoensathien V, Ejeder TT. Study raises questions about measurement of 'additionality, ' or maintaining domestic health spending amid foreign donations. Health Aff (Millwood) 2012; 31:417-425.
16. Kim J, Lutz B, Dhaliwal M, O'Malley J. The ' AIDS and MDG s' approach: what is it, why does it matter, and how do we take it forward? Third World Quarterly 2011; 32:141-163.
17. UNDP/UNAIDS. Understanding and acting on critical enablers and development synergies: for strategic investments. New York: UNDP; 2012.
18. Geneau R, Hallen G. Toward a systemic research agenda for addressing the joint epidemics of HIV/AIDS and noncommunicable diseases. AIDS 2012; 26 (Suppl 1):S7-S10.
19. Samb B, Evans T, Dybul M, Atun R, Moatti JP, Nishtar S, et al. An assessment of interactions between global health initiatives and country health systems. Lancet 2009; 373:2137- 2169.
20. Leeper SC, Reddi A. United States global health policy: HIV/AIDS, maternal and child health, and The President's Emergency Plan for AIDS Relief (PEPFAR). AIDS 2010; 24: 2145-2149.
21. Walensky RP, Kuritzkes DR. The impact of the President's Emergency Plan for AIDS Relief (PEPfAR) beyond HIV and why it remains essential. Clin Infect Dis 2010; 50:272-275.
22. Stillwaggon E. AIDS and the ecology of poverty. New York: Oxford University Press; 2006.
23. Hunsmann M. Limits to evidence-based health policymaking: policy hurdles to structural HIV prevention in Tanzania. Soc Sci Med 2012; 74:1477-1485.
24. RethinkHIV. RethinkHIV Expert Panel: outcome document. New York: RethinkHIV; 2011, http://www.rethinkhiv.com/images/Papers/110928095517- b02203b534a64941aa0fcd83f43c6137.pdf [accessed 10 June 2013].
25. Forsythe S, Stover J, Bollinger L. The past, present and future of HIV, AIDS and resource allocation. BMC Public Health 2009; 9 (Suppl 1):S4.
26. Lasry A, Richter A, Lutscher F. Recommendations for increasing the use of HIV/AIDS resource allocation models. BMC Public Health 2009; 9 (Suppl 1):S8.
27. Bautista-Arredondo S, Gadsden P, Harris JE, Bertozzi SM. Optimizing resource allocation for HIV/AIDS prevention programmes: an analytical framework. AIDS 2008; 22 (Suppl 1): S67-S74.
28. Pinkerton SD, Johnson-Masotti AP, Holtgrave DR, Farnham PG. Using cost-effectiveness league tables to compare interventions to prevent sexual transmission of HIV. AIDS 2001; 15:917-928.
29. Moatti JP, Marlink R, Luchini S, Kazatchkine M. Universal access to HIV treatment in developing countries: going beyond the misinterpretations of the 'cost-effectiveness' algorithm. AIDS 2008; 22 (Suppl 1):S59-S66.
30. Stillwaggon E. Complexity, cofactors, and the failure of AIDS policy in Africa. J Int AIDS Soc 2009; 12:12.
31. Lomborg B. Rethink HIV: smarter ways to invest in ending HIV in Sub-Saharan Africa. Cambridge: Cambridge University Press; 2012.
32. Mills AJ, Shillcutt SD. Challenge paper on communicable diseases. Copenhagen, Denmark: Copenhagen Consensus Center; 2004.
33. Drummond M, Stoddart G. Assessment of health producing measures across different sectors. Health Policy 1995; 33:219- 231.
34. Weatherly H, Drummond M, Claxton K, Cookson R, Ferguson B, Godfrey C, et al. Methods for assessing the cost-effectiveness of public health interventions: key challenges and recommendations. Health Policy 2009; 93:85-92.
35. Kenkel D, Suhrcke M. Economic evaluation of the social determinants of health, an overview of conceptual and practical issues. Copenhagen, Denmark: World Health Organization Regional Office for Europe; 2011.
36. Claxton K, Sculpher M, Culyer A. Mark versus Luke? Appropriate methods for the evaluation of public health interventions. CHE Research Paper 31. York, UK: The University of York; 2007.
37. Miller W, Robinson LA, Lawrence RS, Institute of Medicine. Committee to Evaluate Measures of Health Benefits for Environmental H, Safety R. Valuing health for regulatory cost-effectiveness analysis. Washington, DC: National Academies Press; 2006.
38. Chesson HW, Pinkerton SD. Sexually transmitted diseases and the increased risk for HIV transmission: implications for cost-effectiveness analyses of sexually transmitted disease prevention interventions. J Acquir Immune Defic Syndr 2000; 24:48-56.
39. Baird S, Chirwa E, McIntosh C, Ozler B. The short-term impacts of a schooling conditional cash transfer program on the sexual behavior of young women. Health Econ 2010; 19 (Suppl):55- 68.
40. Ozler B. Unpacking the impacts of a randomized CCT program in Malawi.World Bank; undated. See worldbank.org/SAFETYNETSANDTRANSFERS/Resources/ 281945-1131468287118/1876750-1231881410497/Ozler-SIHR-DC-090112.pdf
41. Baird SJ, McIntosh CT, Ozler B. Cash or conditioñ Evidence from a cash transfer experiment. Quar J Econ 2011; 126:1709- 1753.
42. King EM, Klasen S, Porter M. Women and development. 2008 Challenge Paper. Copenhagen: Copenhagen Consensus Center; 2007.
43. Vassall A, Remme M, Watts C. Social policy interventions to enhance the HIV/AIDS response in Sub-Saharan Africa. In: Lomborg B. editor. Rethink HIV: smarter ways to invest in ending HIV in Sub-Saharan Africa Cambridge: Cambridge University Press; 2012. pp. 238-292.
44. Cleary SM, McIntyre D, Boulle AM. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa: a primary data analysis. Cost Eff Resour Alloc 2006; 4:20.
45. Shillcutt SD, Walker DG, Goodman CA, Mills AJ. Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics 2009; 27:903-917.
46. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7:518-528.
47. Birch S, Gafni A. The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost-effectiveness threshold. J Health Serv Res Policy 2006; 11:46-51.
48. Edejer TT-T. Making choices in health WHO guide to costeffectiveness analysis. Geneva: World Health Organization; 2003.
49. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997; 16:1-31.
50. Johri M, Ako-Arrey D. The cost-effectiveness of preventing mother-to-child transmission of HIV in low- and middleincome countries: systematic review. Cost Eff Resour Alloc 2011; 9:3.
51. Sempa J, Ssennono M, Kuznik A, Lamorde M, Sowinski S, Semeere A, et al. Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda. BMC Public Health 2012; 12:736.
52. Hummel-Rossi B, Ashdown J. The state of cost-benefit and costeffectiveness analyses in education. Rev Educ Res 2002; 72:1- 30.
53. Levin H, McEwan P. Cost-effectiveness analysis. 2nd ed. Thousand Oaks, CA: Sage; 2001.
54. Levin HM. Waiting for Godot: cost-effectiveness analysis in education. In: Light R. editor. Evaluation findings that surprise San Francisco: Jossey Bass; 2002. pp. 55-68.
55. Dhaliwal I, Duflo E, Glennester R, Tulloch C. Comparative costeffectiveness analysis to inform policy in developing countries: a general framework with applications for education.Abdul Latif Jameel Poverty Action Lab (J-PAL); 2011, http://www.povertyactionlab.org/publication/cost-effectiveness [accessed 12 September 2012].
56. Birch S, Gafni A. Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be? J Health Econ 1992; 11:279-296.
57. Remme M, Vassall A, Lutz B, Watts C. Paying girls to stay in school: a good return on HIV investment? Lancet 2012; 379: 2150.
58. Giles-Corti B, Foster S, Shilton T, Falconer R. The co-benefits for health of investing in active transportation. N S W Public Health Bull 2010; 21:122-127.
59. Malawi Government. 2011/12 Budget Statement. Finance Mo. Lilongwe: Malawi Government; 2011.
60. Gilmour S, Hamakawa T, Shibuya K. Cash-transfer programmes in developing countries. Lancet 2013; 381:1254- 1255.
61. WHO. Intersectoral Governance for health in all policies. Copenhagen, Denmark: WHO, on behalf of the European Observatory on Health Systems and Policies; 2012.
62. Johansson P, Tillgren P. Financing intersectoral health promotion programmes: some reasons why collaborators are collaborating as indicated by cost-effectiveness analyses. Scand J Public Health 2011; 39:26-32.
63. Hultberg EL, Lonnroth K, Allebeck P. Effects of a co-financed interdisciplinary collaboration model in primary healthcare on service utilisation among patients with musculoskeletal disorders. Work 2007; 28:239-247.
64. Acosta AM, Fanzo J. Fighting maternal and child malnutrition: analysing the political and institutional determinants of delivering a national multisectoral response in six countries.Institute of Development Studies; 2012, http://www.ids.ac.uk/files/dmfile/DFID-ANG-Synthesis-April2012.pdf [Accessed on 7 March 2013].
65. Verguet S, Laxminarayan R, Jamison DT, Universal Public Finance of Tuberculosis Treatment in India. An extended costeffectiveness analysis. in disease control priorities in developing countries. Working paper no. 1. 3rd ed.Universal Public Finance of Tuberculosis Treatment in India; 2012, http://www.dcp-3.org/sites/default/files/resources/DCP3-WP1%20%281%29.pdf?issu [accessed on 10 June 2013].
66. Baltussen R, Niessen L. Priority-setting of health interventions: the need for multicriteria decision analysis. Cost-Effectiveness and Resource Allocation 2006; 6:4.
67. Cleary SM, McIntyre D. Affordability: the forgotten criterion in health-care priority setting. Health Econ 2009; 18:373-375.
68. Sendi PP, Briggs AH. Affordability and cost-effectiveness: decision- making on the cost-effectiveness plane. Health Econ 2001; 10:675-680.
69. RethinkHIV. Priorities. Rush Foundation; 2011, http://www.rethinkhiv.com/ priorities [accessed 7 March 2013].
70. Evans P. Development as institutional change: the pitfalls of monocropping and the potentials of deliberation. Studies Comp Int Develop 2004; 38:30-52.
71. Heller PS. The prospects of creating 'fiscal space' for the health sector. Health Policy Plan 2006; 21:75-79.